{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:45:30Z","timestamp":1788515130081,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bmc.2021.116350","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:39:49Z","timestamp":1628401189000},"page":"116350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton"],"prefix":"10.1016","volume":"47","author":[{"given":"Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116350_b0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2021.116350_b0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116350_b0015","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2021.116350_b0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","article-title":"Emerging connectivity of programmed cell death pathways and its physiological implications","volume":"21","author":"Bedoui","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2021.116350_b0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2021.116350_b0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2021.116350_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.10.009","article-title":"Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy","volume":"195","author":"Yamaguchi","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2021.116350_b0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.blre.2017.08.004","article-title":"Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances","volume":"32","author":"Wu","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmc.2021.116350_b0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gde.2010.12.001","article-title":"Apoptosis and oncogenesis: give and take in the BCL-2 family","volume":"21","author":"Llambi","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.bmc.2021.116350_b0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.seminoncol.2003.08.015","article-title":"Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists","volume":"30","author":"Wang","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bmc.2021.116350_b0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2021.116350_b0060","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.bmcl.2016.03.032","article-title":"Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity","volume":"26","author":"Hennessy","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116350_b0065","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2021.116350_b0070","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0000000000000408","article-title":"BCL-2 Inhibitors, present and future","volume":"25","author":"Ryan","year":"2019","journal-title":"Cancer J"},{"key":"10.1016\/j.bmc.2021.116350_b0075","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1002\/cam4.3090","article-title":"Bcl-2\/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma","volume":"9","author":"Yi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.bmc.2021.116350_b0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.htct.2018.09.001","article-title":"Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia","volume":"41","author":"Campos","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.bmc.2021.116350_b0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing towards the dream","volume":"3","author":"Arkin","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2021.116350_b0090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nature06526","article-title":"Reaching for high-hanging fruit in drug discovery at protein-protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2021.116350_b0095","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2174\/1568026619666191011163410","article-title":"Targeting protein-protein interaction with covalent small-molecule inhibitors","volume":"19","author":"Li","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0100","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2174\/1568026618666180601080824","article-title":"A structural perspective on the modulation of protein-protein interactions with small molecules","volume":"18","author":"Demirel","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/acs.jmedchem.5b01888","article-title":"Expanding the cancer arsenal with targeted therapies: disarmament of the antiapoptotic Bcl-2 proteins by small molecules","volume":"60","author":"Yap","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0110","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/j.bmc.2019.05.003","article-title":"Design, synthesis and preliminary bioactivity studies of indomethacin derivatives as Bcl-2\/Mcl-1 dual inhibitors","volume":"27","author":"Chen","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejmech.2018.09.059","article-title":"Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin","volume":"159","author":"Liu","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0120","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1021\/jm300178u","article-title":"Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold","volume":"55","author":"Zhou","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0125","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.bmc.2015.03.024","article-title":"Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors","volume":"23","author":"Wan","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0130","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/jm800669s","article-title":"Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins","volume":"51","author":"Park","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0135","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2021.116350_b0140","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11523-019-00673-1","article-title":"Venetoclax: a review in relapsed\/refractory chronic lymphocytic leukemia","volume":"14","author":"Scott","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.bmc.2021.116350_b0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/13543776.2019.1627327","article-title":"A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent","volume":"29","author":"\u017digart","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2021.116350_b0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2019.01.040","article-title":"Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax)","volume":"142","author":"Lever","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2021.116350_b0155","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2021.116350_b0160","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1021\/jm061152t","article-title":"Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL","volume":"50","author":"Bruncko","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116350_b0165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621003588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621003588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:16:06Z","timestamp":1760836566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621003588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"alternative-id":["S0968089621003588"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116350","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116350"}}